Diagenode

Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes.


Yi G, Wierenga ATJ, Petraglia F, Narang P, Janssen-Megens EM, Mandoli A, Merkel A, Berentsen K, Kim B, Matarese F, Singh AA, Habibi E, Prange KHM, Mulder AB, Jansen JH, Clarke L, Heath S, van der Reijden BA, Flicek P, Yaspo ML, Gut I, Bock C, Schuringa JJ

Global investigation of histone marks in acute myeloid leukemia (AML) remains limited. Analyses of 38 AML samples through integrated transcriptional and chromatin mark analysis exposes 2 major subtypes. One subtype is dominated by patients with NPM1 mutations or MLL-fusion genes, shows activation of the regulatory pathways involving HOX-family genes as targets, and displays high self-renewal capacity and stemness. The second subtype is enriched for RUNX1 or spliceosome mutations, suggesting potential interplay between the 2 aberrations, and mainly depends on IRF family regulators. Cellular consequences in prognosis predict a relatively worse outcome for the first subtype. Our integrated profiling establishes a rich resource to probe AML subtypes on the basis of expression and chromatin data.

Tags
Antibody

Share this article

Published
January, 2019

Source

Products used in this publication

  • Antibody ChIP-seq grade icon
    C15410196
    H3K27ac polyclonal antibody - Premium
  • Antibody ChIP-seq grade icon
    C15410195
    H3K27me3 polyclonal antibody - Premium
  • Antibody ChIP-seq grade icon
    C15410192
    H3K36me3 polyclonal antibody - Premium
  • Antibody ChIP-seq grade icon
    C15410194
    H3K4me1 polyclonal antibody - Premium
  • Antibody ChIP-seq grade icon
    C15410003-50
    H3K4me3 polyclonal antibody - Premium
  • Antibody ChIP-seq grade icon
    C15410193
    H3K9me3 polyclonal antibody - Premium

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics